Committed to Making Insulins Available & Accessible
Biocon Biologics and Viatris Launch SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection in U.S. as the First-Ever Interchangeable Biosimilar
Stories - Archive
Addressing the COVID-19 Pandemic
The Biocon Group addressed the COVID-19 pandemic unitedly with undeterred spirit and unwavering purpose.
The 10-cent answer to diabetes At 10 cents a day, our insulin is a game changer in the developing world.
Despite the capital-intensive nature of insulin production, Biocon has succeeded in expanding access to insulin therapy in India and key global markets by pursuing an innovation strategy that is rooted in affordability.
